Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07310290 · ClinicalTrials.gov registry record
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
A clinical trial of Migraine, sponsored by AbbVie.
- Recruiting
- Registry status
- 189
- Enrollment target
- 3
- Study locations
NCT07310290: Recruiting study of Migraine, sponsored by AbbVie.
NCT07310290 is a study of Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 189 participants, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (47% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07310290, a study of Migraine, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- 189 participants
- Enrollment target
- 3
- Study locations
Study Summary
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks. Ubrogepant is a drug that is approved for the acute treatment of migraine in adults. Approximately 189 participants will be enrolled in approximately 15 sites across the US. Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 13 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Primary Outcome
Prodrome is often the earliest phase of migraine attack and consists of various symptoms including sensitivity to light, fatigue, neck pain, sensitivity to sound, dizziness and difficulty thinking/concentrating.
Conditions Studied
Study Locations (3)
California
- Neurology and Pain Specialty Center /ID# 278508 - Aliso Viejo
Illinois
- Chicago Headache Center & Research Inst /ID# 272345 - Naperville
Nebraska
- Tri City Research Center, LLC /ID# 278800 - Grand Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2027-03 |
What NCT07310290 shows while recruiting
NCT07310290 is an observational study that tracks outcomes without assigning an intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, below the 356-participant average among 102 other Migraine trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 0 interventions.
NCT07310290 reports a single indexed study location in California, Illinois, Nebraska.
Frequently Asked Questions
What is clinical trial NCT07310290 about?
NCT07310290 is a clinical study titled "Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks". Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks. Ubrogep...
What is the current status of trial NCT07310290?
This trial is currently recruiting. The enrollment target is 189 participants. The study started on 2026-01-27. Estimated completion is 2027-03.
What conditions does trial NCT07310290 study?
This clinical trial studies the following conditions: Migraine.
Who is sponsoring clinical trial NCT07310290?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07310290 being conducted?
This trial has 3 study locations across California, Illinois, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07310290's enrollment target sits among peer trials
189 43rd of 102 higher than 60 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI